

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
16 November 2023 (16.11.2023)



(10) International Publication Number
WO 2023/218410 A1

(51) International Patent Classification:

A61K 31/437 (2006.01) A61P 35/02 (2006.01)
A61K 31/706 (2006.01)

(21) International Application Number:

PCT/IB2023/054902

(22) International Filing Date:

11 May 2023 (11.05.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/341,210	12 May 2022 (12.05.2022)	US
63/350,524	09 June 2022 (09.06.2022)	US
63/370,170	02 August 2022 (02.08.2022)	US

(71) Applicant: **BEIGENE SWITZERLAND GMBH**
[CH/CH]; Aeschengraben 27, Basel 4051 (CH).

(72) Inventor: **SIMPSON, David**; No. 30 Science Park Rd.,
Zhong-Guan-Cun Life Science Park, Changping District,
Beijing, Beijing 102206 (CN).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: METHODS OF TREATING MYELOID MALIGNANCIES USING BCL-2 INHIBITOR




FIG. 1

(57) Abstract: The present disclosure provides methods of treating myeloid malignancies in a subject with a Bcl-2 inhibitor, in particular 2-((1H-pyrrolo[2,3-b]pyridin-5-yl)oxy)-N-((4-(((1R,4R)-4-hydroxy-4-methylcyclohexyl)methyl)amino)-3-nitrophenyl)sulfonyl)-4-(2-((S)-2-isopropylphenyl)pyrrolidin-1-yl)-7-azaspiro[3.5]nonan-7-yl)benzamide or a pharmaceutically acceptable salt thereof, in combination with azacitidine.

[Continued on next page]

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *of inventorship (Rule 4.17(iv))*

Published:

- *with international search report (Art. 21(3))*
- *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*